Psoriasis

Lower fertility rate and increased risk of pregnancy loss were identified among women with moderate to severe psoriasis, according to a new study.

Patients and physicians often disagree on the patient’s disease severity, creating a relationship barrier and frustration among both parties.

The most severe psoriasis was associated with the lowest blood levels of vitamin D and the greatest affected body surface area.

No significant differences regarding racial backgrounds were found when measuring access to biologics among adult patients with psoriasis living in the United States, according to one study.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Researchers find a causal relationship between metabolic syndrome (MetS) and its components for increased risk of psoriasis.

Patients who were younger and had more disease-related skin symptoms were more likely to express interest in the intervention.

The study adds to a growing amount of literature documenting the impact of psoriasis on mental health.

People with psoriasis were also more likely to have pulmonary comorbidities compared with those who did not have psoriasis.

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.

Researchers laid out 6 position statements for the technology in this patient population.

However, overall fertility rates of patients with psoriasis were similar to national fertility trends, authors found.

Findings are based on a case-control study carried out in Brazil.

Findings are based on a meta-analysis of 51 studies and 739 pregnancies.

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time

Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics.

Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment.

After 1 year, overall treatment switch rates were 14.4%, while after 2 years, switch rates were 26%.

Strict inclusion and exclusion criteria in clinical trials means findings on health-related quality of life (HRQOL) may not be generalizable to the real-world setting.

Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.

Approximately one quarter of patients who have psoriasis experience disease onset before adulthood.

Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP).